Point72 Asset Management
UTHR icon

Point72 Asset Management’s United Therapeutics UTHR Stock Holding History

Point72 Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,600
Closed -$6.29M – 4615
2026
Q1 		$6.29M Buy
+10,600
New +$5.28M 0.01% 1545

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Point72 Asset Management's UTHR Position: Q2 2026 in Review

Point72 Asset Management increased its United Therapeutics (UTHR) stake by 35% in Q2 2026, buying an estimated $29.2M and bringing the position to 201,159 shares worth $109M. The position accounts for 0.12% of the portfolio, ranked #181.

Point72 Asset Management first reported a position in UTHR in Q3 2014 and has held it in 23 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Point72 Asset Management held 201,159 shares of United Therapeutics worth $109M as of Q2 2026.
  • Point72 Asset Management bought 51,856 United Therapeutics shares in Q2 2026, an estimated $29.2M.
  • United Therapeutics made up 0.12% of Point72 Asset Management's portfolio in Q2 2026, its #181 holding.
  • Point72 Asset Management first reported a position in United Therapeutics in Q3 2014 and has held it in 23 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.